详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

68Ga-PSMA PET/CT Identifies "Pseudo-progression" of Bone Lesions in Prostate Cancer Observed on 68Ga-DOTA-IBA PET/CT

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Departments of Nuclear Medicine, The First People's Hospital of Mianyang, Sichuan Mianyang 404 Hospital, Mianyang. [2]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University. [3]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province. [4]Laboratory for Targeted Radiopharmaceuticals Creation. [5]Institute of Nuclear Medicine, Southwest Medical University, Jiangyang, Luzhou, Sichuan, P. R. China.

出处：

DOI：

ISSN：

关键词： pseudo-progression DOTA-IBA PSMA response evaluation

摘要：

We report a case where 68Ga-PSMA PET/CT distinguished "pseudo-progression" from progression observed on 68Ga-DOTA-IBA PET/CT. In a 75-year-old man with metastatic castration-resistant prostate cancer (mCRPC), 68Ga-DOTA-IBA PET/CT revealed markedly increased tracer uptake in bone metastases compared with pretreatment imaging, suggesting radiologic progression. However, 68Ga-PSMA-11 PET/CT images demonstrated the complete metabolic response (PERCIST 1.0), revealing "pseudo-progression" of bone lesions in 68Ga-DOTA-IBA, especially when combined with clinical symptoms, PSA, and ALP levels.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 3 区医学

小类 | 3 区核医学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区核医学

第一作者：

第一作者机构： [1]Departments of Nuclear Medicine, The First People's Hospital of Mianyang, Sichuan Mianyang 404 Hospital, Mianyang. [2]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University. [3]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province. [4]Laboratory for Targeted Radiopharmaceuticals Creation. [5]Institute of Nuclear Medicine, Southwest Medical University, Jiangyang, Luzhou, Sichuan, P. R. China.

通讯作者：

通讯机构： [1]Departments of Nuclear Medicine, The First People's Hospital of Mianyang, Sichuan Mianyang 404 Hospital, Mianyang. [2]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University. [3]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province. [4]Laboratory for Targeted Radiopharmaceuticals Creation. [5]Institute of Nuclear Medicine, Southwest Medical University, Jiangyang, Luzhou, Sichuan, P. R. China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Increased Uptake of 68Ga-DOTA-IBA in Lymph Node and Meningeal Metastases of Breast Cancer [2]Increased Uptake of 68Ga-DOTA-IBA in Lung NUT Carcinoma [3]Incidental Uptake of 68Ga-DOTA-IBA in Lung Cancer [4]Comparison of 18F-FDG and 68Ga-DOTA-IBA in detecting bone metastases: a lesion-basis study [5]Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases [6]68Ga-DOTA-IBA Uptake in Meningioma and Liver Metastasis of Breast Cancer [7]Increased Uptake of 68Ga-DOTA-IBA in Lymph Node Metastases of Prostate Cancer [8]A New Radiopharmaceutical 225 Ac-DOTA-IBA in the Treatment of a Case of Bone Metastases [9]Comparison of the relative diagnostic performance of 68Ga-DOTA-IBA and 18F-NaF for the detection of bone metastasis [10]<sup>177</sup>Lu-DOTA-IBA治疗肿瘤骨转移的临床实践指南（2025年版）